Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 4/20 | 0.57 |
| ▸ | MGLL | Q99685 | 2/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | CBS | P35520 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19007852 | 0.98 | ALDH1A1 (0.59) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL14368556 | 0.93 | TDP1 (0.61) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL28600680 | 0.93 | ALDH1A1 (0.66) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL28434793 | 0.93 | ALDH1A1 (0.66) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10621326 | 0.93 | ALDH1A1 (0.66) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4941879 | 0.93 | ALDH1A1 (0.66) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL118235 | 0.93 | ALDH1A1 (0.66) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2926392 | 0.93 | ALDH1A1 (0.66) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL20624816 | 0.93 | ALDH1A1 (0.66) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10621313 | 0.93 | ALDH1A1 (0.66) | MAPTRXFP1ALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815766-B2 | Process for double carbonylation of allyl ethers to corresponding diesters | EVONIK DEGUSSA GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-20170174609-A1 | PROCESS FOR DOUBLE CARBONYLATION OF ALLYL ETHERS TO CORRESPONDING DIESTERS | EVONIK DEGUSSA GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174609-A1 | PROCESS FOR DOUBLE CARBONYLATION OF ALLYL ETHERS TO CORRESPONDING DIESTERS | CBR3, CBR1, EPOR | MAPT 3311/4885RXFP1 4759/4885ALDH1A1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.